Search clinical trials for: UT-15C SR (treprostinil diethanolamine) 1mg oral tablets

Total 28 results

Southern Arizona Vascular Institute
Southern Illinois University

Unknown

UT-15C SR in the Treatment of Critical Limb Ischemia

Critical Limb Ischemia

United States
United Therapeutics

Completed

Effect of Food on the Pharmacokinetics of Oral Treprostinil

Pulmonary Arterial Hypertension | Hypertension, Pulmonary

United States
United Therapeutics

Completed

A Pharmacokinetic Substudy of the TDE-PH-304 Protocol

Pulmonary Arterial Hypertension

United States
United Therapeutics

Completed

Three Times Daily Dosing of UT-15C

Healthy

United States
United Therapeutics

Completed

The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil

Pulmonary Arterial Hypertension | Renal Dysfunction

United States
United Therapeutics

Completed

Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension (FREEDOM-C2)

Pulmonary Hypertension

United States, Canada, Germany, Spain, Belgium, Sweden, Israel, France, Italy, Netherlands, Portugal, United Kingdom
United Therapeutics

Completed

FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

Pulmonary Hypertension

United States, China, Israel, Belgium, Canada, France, India, Mexico, Austria, Italy, Netherlands, Poland, Puerto Rico
United Therapeutics

Completed

An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension (FREEDOM-EXT)

Pulmonary Arterial Hypertension

United States, Canada, India, United Kingdom, Spain, Israel, Australia, Belgium, France, Austria, China, Germany, Ireland, Italy, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Sweden
United Therapeutics

Completed

Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil

Pulmonary Arterial Hypertension | Hypertension, Pulmonary

United States
Ochsner Health System
United Therapeutics

Completed

Safety Study of UT-15C SR (Oral Treprostinil) in Patients Undergoing a Lower Limb Endovascular Procedure

Critical Limb Ischemia

United States
United Therapeutics

Completed

Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®

Pulmonary Arterial Hypertension

United States
United Therapeutics

Completed

Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine

Pulmonary Arterial Hypertension

United States
United Therapeutics

Completed

A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension

Pulmonary Hypertension

United States
United Therapeutics

Completed

FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)

Pulmonary Hypertension

United States, United Kingdom, Canada, Spain, Australia, Israel, Germany, Belgium, France, Austria, Italy, Poland, Ireland, Netherlands
United Therapeutics

Completed

Remodulin® to Oral Treprostinil Transition

Pulmonary Arterial Hypertension

United States
United Therapeutics

Withdrawn

FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

Pulmonary Hypertension

United States, Australia, Mexico
United Therapeutics

Completed

Pharmacokinetic Interaction of Oral Treprostinil and Ethanol in Healthy Volunteers (TDE-PH-125)

Healthy

United States
Seung Up Kim

Active, not recruiting

Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Hepatitis B, Chronic | Fibrosis, Liver

Korea, Republic of
Axsome Therapeutics, Inc.

Completed

Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Oral Administration

Obstructive Sleep Apnea | Narcolepsy | Postpartum | Excessive Sleepiness | Excessive Daytime Somnolence

United States
Future Medicine
Futuremedicine Australia

Recruiting

FM101 Safety, Tolerability, Efficacy Study in the Patients With Ocular Hypertension

Ocular Hypertension

Australia
AstraZeneca
Quotient Sciences

Completed

Absolute Bioavailability and ADME Study of Savolitinib in Healthy Male Subjects

Cancer

United Kingdom
Cortendo AB

Completed

Drug Interaction Study of Levoketoconazole and Metformin

Healthy Subjects

United States
Cambridge University Hospitals NHS Foundation Trust
University of Cambridge

Active, not recruiting

Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV Disease (INTENSITY-HIGH)

Cardiovascular Diseases | Atherosclerosis

United Kingdom
Blade Therapeutics

Completed

Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers

Drug Drug Interaction

United States
Actavis Inc.

Completed

A Relative Bioavailability Study of Bupropion Sustained Release 150 mg Tablets Under Fasting Conditions

Healthy

United States
Institute of Hematology and Blood Transfusion,...
CZECRIN - Czech Clinical Research Infrastructure Network

Suspended

Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL (Pona-CELL)

Newly Diagnosed | Acute Lymphoblastic Leukemia, Adult | Ph+ ALL

Czechia
Chong Kun Dang Pharmaceutical

Unknown

Study to Compare the Pharmacokinetic Characteristics and Safety of Dilatrend SR Capsule 32mg and Dilatrend Tablet 25mg

Essential Hypertension | Congestive Heart Failure | Chronic Stable Angina

Korea, Republic of
Ukrainian Medical Stomatological Academy

Completed

Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease (EFFORT)

Adverse Effect | Atherosclerosis, Coronary | Insulin Resistance Syndrome

Ukraine

Search clinical trials for: UT-15C SR (treprostinil diethanolamine) 1mg oral tablets

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations